N	Concordance
1	mide, methotrexate, mercaptopurine, and carmustine, many of which should be non
2	l, vincristine, vinblastine, bleomycin, carmustine, cisplatin, asparaginase, pr
3	oma  multiforme treated with concurrent carmustine (BCNU) and radiotherapy vs. 3
4	reated with high-dose cyclophosphamide, carmustine, and etoposide and autologous
5	 (Alkeran), cyclophosphamide (Cytoxan), carmustine (BCNU), vincristine (Oncovin)
6	form are targets of the cytostatic drug carmustine (BCNU), no immunologic cross-
7	en. For example, in the dose-escalation carmustine (BCNU) wafer protocol that NA
8	ne followed 1 hour later by intravenous carmustine every 6 weeks.  Additional co
9	o evaluate the activity and toxicity of carmustine (BCNU) and cisplatin administ
10	optimum dose is determined; the dose of carmustine is then increased  in additio
11	art of  therapy.  Patients also receive carmustine intravenous infusion over 1-2
12	     tumors correlates with response to carmustine therapy. We therefore       e
13	been topical  nitrogen mustard, topical carmustine or a phototherapy (UVB, PUVA,
14	 or to high dose BEAM chemotherapy with carmustine, etoposide, cytarabine, and m